Life science, also known as bioscience, comprises several branches of science, including biology, medicine, and ecology among others. This comprehensive scientific division is emerging as a burgeoning private equity sector with a phalanx of funds hitting the market looking to invest in firms that are developing ideas in biotechnology, pharmaceuticals and biomedical technologies.
Preqin is compiling a research report crammed with key stats and facts on private equity life science focused fundraising. The report reveals that private equity funds focused on life sciences have raised in excess of USD 17 billion in 2007 and USD 28 billion in 2008, but far less in 2009 to date, largely as a consequence of market conditions affecting private equity fund managers’ ability to attract capital for their vehicles.
The report continues by examining life science private equity fundraising by regional focus, exposing the dominance of US focused funds in this sector. In addition to data on fundraising and regional preferences, the report discovers the fundraising sector as almost wholly comprised of venture vehicles, while also indentifying life science funds that have recently closed, and outlining the number life science funds currently on the road.
Information for this research was taken from Preqin’s Funds in Market online module.